1. Home
  2. TNGX vs GEVO Comparison

TNGX vs GEVO Comparison

Compare TNGX & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • GEVO
  • Stock Information
  • Founded
  • TNGX 2014
  • GEVO 2005
  • Country
  • TNGX United States
  • GEVO United States
  • Employees
  • TNGX N/A
  • GEVO N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • GEVO Major Chemicals
  • Sector
  • TNGX Health Care
  • GEVO Industrials
  • Exchange
  • TNGX Nasdaq
  • GEVO Nasdaq
  • Market Cap
  • TNGX 351.2M
  • GEVO 246.8M
  • IPO Year
  • TNGX N/A
  • GEVO 2011
  • Fundamental
  • Price
  • TNGX $5.44
  • GEVO $1.34
  • Analyst Decision
  • TNGX Strong Buy
  • GEVO Buy
  • Analyst Count
  • TNGX 6
  • GEVO 2
  • Target Price
  • TNGX $12.20
  • GEVO $7.58
  • AVG Volume (30 Days)
  • TNGX 3.9M
  • GEVO 5.1M
  • Earning Date
  • TNGX 08-06-2025
  • GEVO 08-07-2025
  • Dividend Yield
  • TNGX N/A
  • GEVO N/A
  • EPS Growth
  • TNGX N/A
  • GEVO N/A
  • EPS
  • TNGX N/A
  • GEVO N/A
  • Revenue
  • TNGX $40,990,000.00
  • GEVO $42,034,000.00
  • Revenue This Year
  • TNGX N/A
  • GEVO $1,022.79
  • Revenue Next Year
  • TNGX N/A
  • GEVO $12.26
  • P/E Ratio
  • TNGX N/A
  • GEVO N/A
  • Revenue Growth
  • TNGX 10.09
  • GEVO 145.38
  • 52 Week Low
  • TNGX $1.03
  • GEVO $0.48
  • 52 Week High
  • TNGX $12.02
  • GEVO $3.39
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 74.98
  • GEVO 53.86
  • Support Level
  • TNGX $4.60
  • GEVO $1.17
  • Resistance Level
  • TNGX $5.63
  • GEVO $1.39
  • Average True Range (ATR)
  • TNGX 0.56
  • GEVO 0.09
  • MACD
  • TNGX -0.05
  • GEVO 0.00
  • Stochastic Oscillator
  • TNGX 85.47
  • GEVO 54.13

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About GEVO Gevo Inc.

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.

Share on Social Networks: